登录新浪财经APP 搜索【信披】查看更多考评等级 目前，*ST长药正陷入多重危机：旗下光伏子公司河北羿珩科技因资金紧张已停产；公司涉及多起诉讼，涉案金额累计超1.5亿元。财务造假、经营困境与退 市风险相互交织，使其成为资本市场又一高风险案例。截至2025年三季度末，*ST长药股东户数超1.4万户，绝大多数为中小投资者。随着退市临近，投资者 面临本金归零风险，而现有处罚机制能否转化为有效赔偿，成为市场关注焦点。 系统虚增利润超1.6亿 证监会调查显示，*ST长药本次财务造假行为具有系统性、跨年度特征，主要源于其于2020年以现金方式收购的控股子公司湖北长江星医药股份有限公司。 公开资料显示，收购完成后，长江星原实际控制人罗明继续担任该公司董事长、总经理，全面负责经营管理，并对2020年至2022年的净利润等指标作出了业 绩承诺。此次造假正是发生在业绩承诺期及后续期间。 根据证监会《行政处罚事先告知书》及公司相关公告，造假的具体实施主体为长江星旗下两家子公司，湖北长江源制药有限公司和湖北新峰制药有限公司。 在2021年至2023年期间，这两家子公司通过制作虚假的原材料入库单、产成品出库单、销售发货单等全套单据，在 ...

Core Viewpoint - Trina Solar's stock price has increased by 5.34% to 17.16 CNY as of December 26, 2025, with a total market capitalization of 40.198 billion CNY, ranking 10th in the photovoltaic equipment sector [1]. Group 1: Shareholder Changes - As of December 10, 2025, the number of shareholders for Trina Solar is 54,100, a decrease of 1.27% from the previous month [1][3]. - The average number of shares held per shareholder increased from 39,800 to 43,300 shares, with an average market value of 718,000 CNY per shareholder [1]. Group 2: Company Announcements - Trina Solar plans to hold its sixth extraordinary general meeting on December 29, 2025, to review three proposals, including engaging in futures, options, and foreign exchange hedging for 2026 with a maximum margin of 3 billion CNY and foreign exchange hedging not exceeding 1 billion USD [1]. - The company will increase its registered capital from approximately 2.179 billion CNY to about 2.343 billion CNY due to the conversion of convertible bonds, and will adjust its board committee to focus on strategy and sustainable development [1]. - Trina Solar's wholly-owned subsidiary has completed the sale of its 5GW component factory assets in the U.S. to T1 Energy, Inc., resulting in a total holding of 17.4% of T1's common stock [2][3].

Core Viewpoint - The China Securities Regulatory Commission (CSRC) has announced severe penalties against Changjiang Pharmaceutical Holdings Co., Ltd. (*ST Changyao) for serious financial fraud, which includes a proposed fine of 10 million yuan for the company and 31 million yuan for 14 responsible individuals, along with a lifetime ban for the former general manager, Luo Ming [4][6]. Financial Fraud Details - *ST Changyao has inflated its revenue and profits for three consecutive years, violating securities laws. The company is facing a potential forced delisting due to these serious violations [4][7]. - The company reported inflated revenues of 215.32 million yuan, 283.74 million yuan, and 233.63 million yuan for the years 2021, 2022, and 2023, respectively, which accounted for 9.12%, 17.57%, and 19.51% of the disclosed revenue for those years [6]. - The inflated profit totals were 56.40 million yuan, 63.38 million yuan, and 43.71 million yuan for the same years, representing 35.62%, 88.23%, and 6.42% of the disclosed profit totals [6]. Regulatory Actions - The CSRC has initiated an investigation into the practices of intermediary institutions involved, with potential penalties for any violations found [4][6]. - The company is the 15th listed firm this year to face potential forced delisting due to financial fraud [4]. Company Performance - *ST Changyao has reported continuous losses, with a net profit of -210 million yuan for the first three quarters of 2025, a year-on-year decrease of 15.89% [8]. - The stock price has been declining since the investigation began, closing at 1.47 yuan per share on December 26, with a total market value of only 515 million yuan [10].

Core Viewpoint - The China Securities Regulatory Commission (CSRC) has taken serious action against Changjiang Pharmaceutical Holdings Co., Ltd. (*ST Changyao) for significant financial fraud, leading to the initiation of delisting procedures by the Shenzhen Stock Exchange [2][5]. Group 1: Regulatory Actions - The CSRC has issued an administrative penalty notice to *ST Changyao for false reporting of financial data over three consecutive years, resulting in a proposed fine of 10 million yuan for the company and a total of 31 million yuan for 14 responsible individuals [5][7]. - The former general manager, Luo Ming, faces a lifetime ban from the securities market due to his role in the fraud [5][7]. - The CSRC is also investigating the practices of intermediary institutions involved, with potential criminal referrals based on findings [5][6]. Group 2: Financial Misconduct Details - *ST Changyao inflated its revenue and profits from 2021 to 2023, with reported inflated revenues of 215.32 million yuan, 283.74 million yuan, and 233.63 million yuan, representing 9.12%, 17.57%, and 19.51% of the disclosed revenues for those years respectively [6]. - The company also reported inflated profit totals of 56.40 million yuan, 63.38 million yuan, and 43.71 million yuan, which accounted for 35.62%, 88.23%, and 6.42% of the disclosed profit totals for the respective years [6][7]. - In 2022, *ST Changyao's failure to properly recognize losses related to a project led to an additional profit inflation of 4.55 million yuan, which was 6.34% of the disclosed profit total for that year [7]. Group 3: Company Performance and Market Impact - *ST Changyao has been experiencing continuous losses, with a net profit of -210 million yuan for the first three quarters of 2025, a year-on-year decrease of 15.89% [10]. - The company's stock price has been declining since the investigation began, closing at 1.47 yuan per share on December 26, with a total market value of only 515 million yuan [12]. - As of September 2023, *ST Changyao had only 14,233 A-share shareholders, with an average holding value of 95,300 yuan [12].

Core Viewpoint - The China Securities Regulatory Commission (CSRC) has taken serious action against Changjiang Pharmaceutical Holdings Co., Ltd. (*ST Changyao) for significant financial fraud, leading to potential delisting procedures by the Shenzhen Stock Exchange [2][5][10]. Group 1: Financial Fraud Details - *ST Changyao has been found to have inflated revenue and profits for three consecutive years, violating securities laws [5][8]. - The company is facing a proposed fine of 10 million CNY, with 14 responsible individuals facing a total fine of 31 million CNY, including a lifetime ban for the former general manager, Luo Ming [5][9]. - The inflated revenues reported were 215.32 million CNY, 283.74 million CNY, and 233.63 million CNY for the years 2021 to 2023, representing 9.12%, 17.57%, and 19.51% of the disclosed revenues respectively [8]. Group 2: Company Performance and Market Impact - As of September 30, 2025, *ST Changyao reported a net profit of -210 million CNY, a year-on-year decrease of 15.89% [11][12]. - The company's stock price has been in decline, closing at 1.47 CNY per share on December 26, 2023, with a total market value of only 515 million CNY [13]. - The company has also announced the suspension of operations for its wholly-owned subsidiary, Yiheng Technology, due to financial difficulties and ongoing losses [11][12].

Group 1 - The company, Jinlang Technology, announced that it will hold the fourth extraordinary general meeting of shareholders on December 26, 2025 [2] - The agenda includes a proposal from the board of directors to adjust the conversion price of "Jinlang Convertible Bond 02" downwards [2]

Core Viewpoint - *ST Changyao has been penalized for three consecutive years of financial fraud, leading to a forced delisting process initiated by the Shenzhen Stock Exchange, marking a significant enforcement trend in the capital market against financial misconduct [1][2][14]. Group 1: Company Overview - *ST Changyao, originally established in 2001 and listed in 2014, transitioned from a photovoltaic equipment company to the pharmaceutical sector in 2020 [6]. - The company acquired a 52.75% stake in Hubei Changjiang Star Pharmaceutical Co., which was integrated into its financial statements, leading to its rebranding as Changyao Holdings [6]. Group 2: Financial Fraud Details - From 2021 to 2023, *ST Changyao's subsidiaries inflated revenues by a total of 733 million yuan and profits by 168 million yuan through falsified documents and non-existent sales [7][8]. - The inflated revenues accounted for 9.12%, 17.57%, and 19.51% of the reported revenues for the respective years, while the inflated profits represented 35.62%, 88.23%, and 6.42% of the total profits [7][8]. Group 3: Regulatory Actions - The company has been fined 10 million yuan, and 14 responsible individuals have been collectively fined 31 million yuan, with the former general manager receiving a lifetime ban from the securities market [10][11]. - The regulatory framework has shifted towards a "three-punishment linkage" approach, encompassing administrative, civil, and criminal penalties for financial fraud [10][11]. Group 4: Market Impact - Following the announcement, *ST Changyao's stock fell by 3.92%, with a market capitalization of 510 million yuan, representing a decline of over 90% from its historical peak [3][4]. - The forced delisting of *ST Changyao marks the 15th instance of a company facing mandatory delisting due to significant violations in 2025, reflecting a zero-tolerance policy in the capital market [14][15]. Group 5: Future Implications - The regulatory environment is evolving, with new rules allowing the China Securities Regulatory Commission to directly penalize third-party accomplices involved in financial fraud [2][12]. - Enhanced investor protection mechanisms are being implemented, including measures for compensation from controlling shareholders of companies that face delisting due to fraud [14][15].

Core Viewpoint - Jinlang Technology announced the adjustment of the conversion price for its "Jinlang Convertible Bond 02" during the 13th meeting of the fourth board of directors, which took place on December 26, 2025 [2] Group 1 - The company held its fourth board meeting on December 26, 2025 [2] - The board approved the proposal to lower the conversion price of the "Jinlang Convertible Bond 02" [2]

Core Viewpoint - The case of *ST Changyao highlights the severe regulatory environment in the capital market, where continuous financial fraud over three years has led to a lifetime ban for key individuals and an inevitable delisting process for the company [2][3][8]. Group 1: Company Overview - *ST Changyao, originally established in 2001 as Kangyue Technology, transitioned from a photovoltaic equipment manufacturer to a pharmaceutical company in 2020 after acquiring a majority stake in Hubei Changjiang Star Pharmaceutical Co., Ltd [4][5]. - The company reported significant financial irregularities, with a total of 7.33 billion yuan in inflated revenue and 1.68 billion yuan in inflated profits from 2021 to 2023 due to fraudulent activities by its subsidiaries [5][6]. Group 2: Regulatory Actions - The Shenzhen Stock Exchange has initiated a mandatory delisting process for *ST Changyao due to its continuous financial fraud, marking it as the 15th company to face such action in 2023, a record high [2][8]. - The regulatory response includes a fine of 10 million yuan for the company and a total of 31 million yuan in fines for 14 responsible individuals, with the former CEO facing a lifetime ban from the securities market [6][7]. Group 3: Broader Regulatory Trends - The case reflects a broader trend of "zero tolerance" towards financial fraud in the capital market, with new regulations stipulating that companies engaging in financial fraud for three consecutive years will face mandatory delisting [8][9]. - The regulatory framework is evolving to include not only administrative penalties but also civil and criminal liabilities, indicating a comprehensive approach to tackling financial misconduct [6][9]. Group 4: Investor Protection - The China Securities Regulatory Commission (CSRC) is enhancing investor protection mechanisms, requiring major shareholders and actual controllers of delisted companies to take proactive compensation measures [9]. - The implementation of new regulations aims to ensure that even after delisting, companies remain accountable for past fraudulent activities, reinforcing the message that financial misconduct will not be tolerated [9].

Core Viewpoint - The case of *ST Changyao highlights the severe regulatory environment in the capital market, with the company facing a forced delisting due to three consecutive years of financial fraud, marking a record number of such cases in 2023 [1][8]. Group 1: Company Overview - *ST Changyao, originally a photovoltaic equipment company, transitioned to the pharmaceutical sector in 2020, acquiring a 52.75% stake in Hubei Changjiang Star Pharmaceutical Co., which led to its financial reporting issues [4][5]. - The company inflated its revenue by a total of 733 million yuan and profits by 168 million yuan from 2021 to 2023 through fraudulent practices [5][6]. Group 2: Regulatory Actions - The Shenzhen Stock Exchange initiated a forced delisting process against *ST Changyao due to its financial misconduct, which is part of a broader trend of stringent regulatory measures against financial fraud in the capital market [1][8]. - The company was fined 10 million yuan, while 14 responsible individuals were collectively fined 31 million yuan, with the former general manager receiving a lifetime ban from the securities market [6][7]. Group 3: Regulatory Environment - The regulatory framework has evolved to impose harsher penalties on companies and individuals involved in financial fraud, with a new rule stating that companies committing fraud for three consecutive years will face mandatory delisting [8][9]. - The efficiency of regulatory actions has improved, with the investigation and issuance of the administrative penalty notice taking only one month [2][7]. Group 4: Investor Protection - The regulatory body has emphasized investor protection, requiring major shareholders and actual controllers of companies facing delisting to take proactive compensation measures for affected investors [8][9]. - New mechanisms for investor rights protection, such as representative litigation and innovative dispute resolution methods, have been introduced to enhance the efficiency of investor claims [8][9].